Felix Sahm Selected Research

Glioblastoma (Glioblastoma Multiforme)

5/2024	A prognostic neural epigenetic signature in high-grade glioma.
2/2024	A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.
1/2024	PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
10/2023	Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial.
1/2023	Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma.
1/2023	Autonomous rhythmic activity in glioma networks drives brain tumour growth.
12/2022	Anaplastic ganglioglioma-A diagnosis comprising several distinct tumour types.
6/2022	Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.
1/2022	Glioblastoma hijacks neuronal mechanisms for brain invasion.
1/2022	DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Felix Sahm Research Topics

Disease

142	Neoplasms (Cancer) 05/2024 - 01/2011
68	Glioma (Gliomas) 05/2024 - 08/2010
45	Glioblastoma (Glioblastoma Multiforme) 05/2024 - 01/2012
38	Meningioma (Meningiomas) 05/2024 - 03/2013
19	Astrocytoma (Pilocytic Astrocytoma) 06/2023 - 02/2011
15	Brain Neoplasms (Brain Tumor) 02/2024 - 02/2015
10	Medulloblastoma 04/2024 - 01/2016
6	Disease Progression 01/2023 - 11/2017
6	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 06/2011
5	Oligodendroglioma 12/2022 - 02/2011
4	Necrosis 12/2023 - 11/2018
4	Lymphoma (Lymphomas) 01/2022 - 09/2014
4	Carcinogenesis 11/2020 - 10/2011
3	Genomic Instability 01/2023 - 01/2019
2	Ependymoma 01/2021 - 01/2019
2	Primitive Neuroectodermal Tumors (PNET) 01/2021 - 02/2016
2	Radiation induced meningioma 11/2020 - 01/2017
2	Leukemia 12/2019 - 01/2017
2	Hypoxia (Hypoxemia) 11/2015 - 01/2014
1	Persistent Infection 05/2024
1	Esophageal Neoplasms (Esophageal Cancer) 05/2024
1	Autoimmune Diseases (Autoimmune Disease) 05/2024

Drug/Important Bio-Agent (IBA)

29	Biomarkers (Surrogate Marker)IBA 05/2024 - 07/2011
27	Proteins (Proteins, Gene)FDA Link 12/2022 - 08/2010
22	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 03/2013
22	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2017
22	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2023 - 02/2011
9	EnzymesIBA 01/2021 - 10/2011
8	Phosphotransferases (Kinase)IBA 01/2023 - 01/2012
8	ParaffinIBA 12/2022 - 06/2011
8	Tryptophan (L-Tryptophan)FDA Link 01/2021 - 01/2011
7	Bevacizumab (Avastin)FDA Link 12/2023 - 10/2015
7	Formaldehyde (Formol)FDA Link 12/2022 - 06/2011
7	Temozolomide (Temodar)FDA LinkGeneric 11/2020 - 06/2013
6	Messenger RNA (mRNA)IBA 07/2023 - 11/2015
6	AntigensIBA 01/2023 - 02/2015
5	Mitogen-Activated Protein KinasesIBA 01/2024 - 01/2018
5	Histones (Histone)IBA 10/2023 - 01/2012
5	VaccinesIBA 10/2023 - 08/2014
5	MicroRNAs (MicroRNA)IBA 01/2023 - 12/2016
5	MethyltransferasesIBA 01/2021 - 01/2014
4	CalciumIBA 02/2024 - 01/2019
4	NucleotidesIBA 01/2024 - 01/2016
4	trametinibIBA 11/2023 - 01/2019
4	Protein Subunit VaccinesIBA 10/2023 - 01/2021
4	ChromatinIBA 01/2023 - 01/2019
4	Transcription Factors (Transcription Factor)IBA 01/2023 - 01/2015
4	KynurenineIBA 01/2021 - 01/2011
4	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2021 - 10/2011
3	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2020
3	Lysine (L-Lysine)FDA Link 10/2023 - 01/2017
3	Methionine (L-Methionine)FDA Link 10/2023 - 01/2017
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2023 - 01/2020
3	Lomustine (CCNU)FDA Link 10/2023 - 11/2017
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2023 - 12/2013
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2021
3	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 12/2013
2	Small Cytoplasmic RNAIBA 02/2024 - 01/2021
2	Coloring Agents (Dyes)IBA 02/2024 - 01/2018
2	AMPA Receptors (AMPA Receptor)IBA 01/2024 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2023 - 01/2014
2	CarbonIBA 12/2023 - 01/2022
2	dabrafenibIBA 11/2023 - 09/2023
2	SynaptophysinIBA 03/2023 - 01/2023
2	CateninsIBA 01/2023 - 01/2019
2	tyrosine receptor (receptor, tyrosine)IBA 01/2023 - 01/2023
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 06/2013
2	capivasertibIBA 01/2022 - 01/2017
2	Reticulin (Reticular Fiber)IBA 01/2022 - 04/2014
2	CollagenIBA 01/2022 - 10/2019
2	Peptides (Polypeptides)IBA 01/2022 - 05/2015
2	Amino Acids FDA Link 01/2021 - 01/2017
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2018
2	Histone Deacetylase InhibitorsIBA 01/2021 - 12/2019
2	Codon (Codons)IBA 01/2021 - 01/2017
2	Essential Amino AcidsIBA 01/2020 - 03/2016
2	NAD (NADH)IBA 01/2020 - 06/2013
2	Small Interfering RNA (siRNA)IBA 04/2019 - 01/2015
2	APTIBA 01/2019 - 11/2018
2	1,4-dinitro-2-methyl-2-buteneIBA 01/2019 - 12/2016
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 02/2014
2	VemurafenibIBA 01/2018 - 09/2012
2	EpitopesIBA 01/2017 - 02/2015
2	alpha-hydroxyglutarateIBA 01/2017 - 01/2012
2	GlucocorticoidsIBA 01/2015 - 01/2014
2	Alkylating AgentsIBA 01/2014 - 06/2013
2	Protein Kinases (Protein Kinase)IBA 01/2014 - 09/2013
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 05/2024
1	boldenone undecylenate (Equipoise)IBA 05/2024
1	Complement System Proteins (Complement)IBA 02/2024
1	Cell-Free Nucleic AcidsIBA 01/2024

Therapy/Procedure

50	Therapeutics 05/2024 - 08/2010
28	Radiotherapy 04/2024 - 12/2015
17	Drug Therapy (Chemotherapy) 01/2024 - 01/2014
7	Immunotherapy 01/2023 - 02/2015
3	Chemoradiotherapy 01/2023 - 01/2013
3	Ligation 02/2015 - 05/2013
2	Salvage Therapy 01/2022 - 01/2019
2	Aftercare (After-Treatment) 01/2021 - 01/2016
1	Heterologous Transplantation (Xenotransplantation) 05/2024